Indications › Obstructive sleep apnea
GLP‑1 drugs in obstructive sleep apnea
Which incretin agents are being studied in obstructive sleep apnea, by whom, and when each trial is due to report. Conditions are grouped from the registry’s own wording, which records the same disease several ways.
- Trials on file
- 10
- Active
- 6
- Results scheduled
- 6
- Molecules studied
- 7
- Sponsors
- 6
FDA-approved for obstructive sleep apnea: tirzepatide. Approval wording is on each drug page, quoted from the label.
1 of the molecules tracked here is FDA-approved for obstructive sleep apnea, so the trials below are asking further questions rather than establishing whether the class works at all. 10 of the 10 trials on file are phase 3 or later — the stage sized for a regulator to act on. 6 distinct sponsors are involved, 9 of the trials run commercially and the rest by universities and hospitals.
Molecules studied in this indication
ecnoglutide · liraglutide · maridebart cafraglutide · mazdutide · retatrutide · semaglutide · tirzepatide
Results due in this indication
Trials on file
All 10 incretin trials recorded in this indication, active first.